Anakinra, a recombinant IL-1 receptor antagonist, blocks the interaction of IL-1β and IL-1α with its receptor and is indicated for RA and cryopyrin-associated periodic syndromes (CAPS). This evidence concerns the gene IL1A and cryopyrin-associated periodic syndrome.